Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water

Cancer Research

Volumn 62, Issue 10, 2002, Pages 2731-2735

  Man, Shan ^a   Bocci, Guido ^a   Francia, Giulio ^a   Green, Shane K ^a   Jothy, Serge ^b   Hanahan, Douglas ^c   Bohlen, Peter ^d   Hicklin, Daniel J ^d   Bergers, Gabriele ^c   Kerbel, Robert S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; DRINKING WATER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; SCID MOUSE; TRANSGENIC MOUSE; TUMOR MODEL; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CELL DIVISION; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; FEMALE; HT29 CELLS; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; PROSTATIC NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037093209     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Redefining the target: Chemotherapeutics as antiangiogenics
2. Antiangiogenic scheduling of lower dose cancer chemotherapy
3. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
4. The logic of anti-angiogenic gene therapy
5. Antiangiogenesis is produced by nontoxic doses of vinblastine
6. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
7. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft
8. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
9. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
10. Effect of p53 status on tumor response to anti-angiogenic therapy
11. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
12. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo
13. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between antiendoglin antibody and cyclophosphamide
14. Metronomic scheduling: The future of chemotherapy?
15. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels
16. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy
17. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor
18. Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin
19. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
20. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
21. Biology and disease of mice
22. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood
23. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: Synthesis and deuterium labeling for applications to metabolite quantification
24. Oxazaphosphorine-specific acquired cellular resistance
25. The hallmarks of cancer